Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)

Bayer exercised option under change-in-control clause in it’s agreement with Loxo Oncology to obtain full licensing rights for the two TRK inhibitor agents ...

Bayer’s darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival with a favorable safety profile compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer

Statistically significant improvement in metastasis-free survival (MFS), with a median MFS of 40.4 months with darolutamide ...

Bayer, Netafim and Ben-Gurion University to collaborate on the integration of digital tools for optimizing drip irrigation of the Nematicide Velum™

Bayer to showcase new data from its growing cancer portfolio at 2019 ASCO GU Cancers Symposium

First presentation of data from the pivotal Phase III ARAMIS trial with the investigational compound darolutamide ...

Bayer committed to fostering partnerships to advance sustainable agriculture

Bayer and Kyoto University form research alliance to discover new treatment approaches against lung diseases

Bayer maintains strong position in Access to Seeds Index

Bayer supports infectious disease surveillance program for companion animals in Africa

Bayer is the major sponsor of an African infectious disease surveillance program aimed at providing novel data on the prevalence and distribution ...

Bayer to showcase latest data for its hemophilia portfolio at EAHAD 2019 Congress

Bayer confirms leading international position as a sustainable company in the areas of climate and water

Board of Management member Dr. Klusik: “We will continue making positive contributions to protecting the climate and water resources” / Numerous investors now use CDP ratings to help reach their investment decisions ...